Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies (Q45058232)

11 July 2018

title

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies (English)

1 reference

11 July 2018

19

Jean-Charles Soria

0 references

Grace K Dy

10

object named as

Grace K Dy

1 reference

11 July 2018

Isabelle Ray-Coquard

7

object named as

Isabelle Ray-Coquard

1 reference

11 July 2018

author name string

Rastislav Bahleda

1

1 reference

11 July 2018

Juneko E Grilley-Olson

2

1 reference

11 July 2018

Ramaswamy Govindan

3

1 reference

11 July 2018

Fabrice Barlesi

4

1 reference

11 July 2018

Laurent Greillier

5

1 reference

11 July 2018

Maurice Perol

6

1 reference

11 July 2018

Dirk Strumberg

8

1 reference

11 July 2018

Beate Schultheis

9

1 reference

11 July 2018

Gérard Zalcman

11

1 reference

11 July 2018

Glen J Weiss

12

1 reference

11 July 2018

Annette O Walter

13

1 reference

11 July 2018

Martin Kornacker

14

1 reference

11 July 2018

Prabhu Rajagopalan

15

1 reference

11 July 2018

David Henderson

16

1 reference

11 July 2018

Hendrik Nogai

17

1 reference

11 July 2018

Matthias Ocker

18

1 reference

11 July 2018

language of work or name

English

0 references

publication date

2 May 2017

1 reference

11 July 2018

British Journal of Cancer

published in

1 reference

11 July 2018

volume

116

1 reference

11 July 2018

issue

12

1 reference

11 July 2018

page(s)

1505-1512

1 reference

11 July 2018

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

copyright license

start time

2 May 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bjc.2017.92

0 references

cites work

Targeting cell cycle regulators in hematologic malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

The history and future of targeting cyclin-dependent kinases in cancer therapy

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Highlights of the Latest Advances in Research on CDK Inhibitors.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Cell cycle kinases as therapeutic targets for cancer

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

PCNA on the crossroad of cancer

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

TFIIH action in transcription initiation and promoter escape requires distinct regions of downstream promoter DNA.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

Understanding the cell cycle.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518866

15 August 2018

Identifiers

DOI

10.1038/BJC.2017.92

1 reference

11 July 2018

Dimensions Publication ID

1085102588

0 references

Fatcat ID

release_xcrzdowoqfaszfmj5ynrcrh26a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xcrzdowoqfaszfmj5ynrcrh26a

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

5518866

1 reference

11 July 2018

PubMed publication ID

28463960

1 reference

11 July 2018